来自MSN1 个月
Liver fibrosis mechanism discovery presents a possible target for new therapies
Sai Wang and several collaborators, how ECM1 acts as a "gatekeeper" in a healthy liver to suppress the activation of the signaling molecule transforming growth factor-β (TGF-β). TGF-β plays a ...
Medscape2 天
Hepatic Fibrosis -- Role of Hepatic Stellate Cell Activation
Platelets are a potent source of growth factors, and are present in the injured liver. [19] Potentially important platelet mediators include platelet-derived growth factor (PDGF), TGF-beta 1 ...
Nature2 年
Sirnaomics: a unique, clinical-phase RNA therapeutic innovator on the global stage
is in phase 1 testing in the treatment of solid tumors and a rare form of liver fibrosis. In common with STP705, STP707 consists of two siRNA oligonucleotides that target TGF-β1 and COX-2 mRNA.
Pharmaceutical Technology21 天
Linavonkibart by Scholar Rock for Colorectal Cancer: Likelihood of Approval
Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition ...